Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Metastatic Neuroendocrine Prostate Cancer
NCT01799278Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2013
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in neuroendocrine prostate cancer (NEPC), small cell prostate cancer (SCCP), sponsored by Weill Cornell Medicine. Started Feb 2013; status: completed.
02
Drugs
alisertib
03
Conditions
neuroendocrine prostate cancer (NEPC)small cell prostate cancer (SCCP)
Beyond the preview
Go deeper on NCT01799278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01799278.